within Pharmacolibrary.Drugs.ATC.M;

model M01AE52
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.95,
    Cl             = 9.499999999999999e-06,
    adminDuration  = 600,
    adminMass      = 500 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.012,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0008333333333333334,
    Tlag           = 600
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>M01AE52</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Naproxen is a nonsteroidal anti-inflammatory drug (NSAID) used to reduce pain, inflammation, and fever. Esomeprazole is a proton pump inhibitor used to decrease gastric acid secretion. The combination is typically used to treat symptoms of osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis in patients at risk of NSAID-associated gastric ulcers. The fixed-dose combination is approved and used in clinical practice.</p><h4>Pharmacokinetics</h4><p>Estimated pharmacokinetic parameters for a fixed dose combination tablet as used in adults, based on available single agent PK literature due to lack of identified original popPK reference for the combination.</p><h4>References</h4><ol><li><p>Wang-Smith, L, et al., &amp; Sostek, M (2012). Pharmacokinetics and relative bioavailability of a fixed-dose combination of enteric-coated naproxen and non-enteric-coated esomeprazole magnesium. <i>Journal of clinical pharmacology</i> 52(5) 670–680. DOI:<a href=&quot;https://doi.org/10.1177/0091270011405500&quot;>10.1177/0091270011405500</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/21628602/&quot;>https://pubmed.ncbi.nlm.nih.gov/21628602</a></p></li><li><p>Choi, Y, et al., &amp; Yu, KS (2015). Comparison of the pharmacokinetics and tolerability of HCP1004 (a fixed-dose combination of naproxen and esomeprazole strontium) and VIMOVO® (a marketed fixed-dose combination of naproxen and esomeprazole magnesium) in healthy volunteers. <i>Drug design, development and therapy</i> 9 4127–4135. DOI:<a href=&quot;https://doi.org/10.2147/DDDT.S86725&quot;>10.2147/DDDT.S86725</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/26257511/&quot;>https://pubmed.ncbi.nlm.nih.gov/26257511</a></p></li><li><p>Dionísio, TJ, et al., &amp; Calvo, AM (2020). Simultaneous separation of naproxen and 6-O-desmethylnaproxen metabolite in saliva samples by liquid chromatography-tandem mass spectrometry: Pharmacokinetic study of naproxen alone and associated with esomeprazole. <i>PloS one</i> 15(8) e0236297–None. DOI:<a href=&quot;https://doi.org/10.1371/journal.pone.0236297&quot;>10.1371/journal.pone.0236297</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/32780750/&quot;>https://pubmed.ncbi.nlm.nih.gov/32780750</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end M01AE52;
